By Elizabeth S. Eaton | Aug 29, 2017 | 11:59 PM GMT
ImmunoGen Inc. (NASDAQ:IMGN) gained $1.12 (17%) to $7.58 on Tuesday after it granted Jazz Pharmaceuticals plc (NASDAQ:JAZZ) an exclusive option to develop and commercialize three of ImmunoGen's antibody-drug
Read the full 289 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury